Familial Alzheimer disease in Latinos

Background: Factors that modify risk related to APOE variants have been examined primarily in unrelated patients and controls, but seldom in family-based studies. Stroke, vascular risk factors, estrogen replacement therapy (ERT), head injury (HI), and smoking have been reported to influence risk of sporadic but not familial Alzheimer disease (AD). Objectives: To examine the potential relationship between these risk factors and APOE, the authors used a family study design in a population in which the APOE-ε4 variant is strongly associated with risk of AD. Methods: Latino families primarily from the Caribbean Islands in which two or more living relatives had dementia were identified in the New York City metropolitan area, the Dominican Republic, and Puerto Rico. A total of 1,498 participants from 350 families underwent a clinical interview, medical and neurologic examinations, neuropsychological testing, and APOE genotyping. Diagnosis was made by consensus using research criteria for AD. Results: APOE-ε4 was associated with a nearly twofold increased risk of AD. A history of stroke was also associated with a fourfold increased risk. A statistical interaction between APOE-ε4 and stroke was observed. Women with an APOE-ε4 who took ERT did not have an increased risk of AD, but in women with a history of stroke ERT was a deleterious effect modifier. Conclusions: APOE-ε4 and stroke independently increase risk of familial Alzheimer disease (AD) among Latinos, and may interact to further increase AD risk. Among women, the risk of AD associated with APOE-ε4 may be attenuated by a history of ERT.

[1]  F. Grodstein,et al.  Apolipoprotein E, cardiovascular disease and cognitive function in aging women , 2005, Neurobiology of Aging.

[2]  W. Scott,et al.  Family-based case-control study of cigarette smoking and Parkinson disease , 2005, Neurology.

[3]  Demetrius M Maraganore,et al.  Blood is thicker than water , 2005, Neurology.

[4]  JoAnn E Manson,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. , 2004, JAMA.

[5]  L. Thal,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[6]  C. Pieper,et al.  Self- or proxy-reported stroke and the risk of Alzheimer disease. , 2004, Archives of neurology.

[7]  R. Mayeux,et al.  Stroke and the risk of Alzheimer disease. , 2003, Archives of neurology.

[8]  Richard Mayeux,et al.  Epidemiology of neurodegeneration. , 2003, Annual review of neuroscience.

[9]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[10]  J. Manson,et al.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[11]  Brenda L Plassman,et al.  Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. , 2002, JAMA.

[12]  N. Patel,et al.  Proinflammatory and Vasoactive Effects of Aβ in the Cerebrovasculature , 2002, Annals of the New York Academy of Sciences.

[13]  C. Colton,et al.  APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress , 2002, Neurobiology of Aging.

[14]  B. Tycko,et al.  Familial Alzheimer disease among Caribbean Hispanics: a reexamination of its association with APOE. , 2002, Archives of neurology.

[15]  K. Jellinger,et al.  Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer’s disease , 2001, European journal of neurology.

[16]  M J Khoury,et al.  Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. , 2001, American journal of epidemiology.

[17]  J. Janowsky,et al.  Hormone replacement therapy and cognition: systematic review and meta-analysis. , 2001, JAMA.

[18]  K. Marder,et al.  Estrogen to treat Alzheimer’s disease: Too little, too late? , 2000, Neurology.

[19]  H C Liu,et al.  Effects of estrogen on cognition, mood, and cerebral blood flow in AD , 2000, Neurology.

[20]  C. DeCarli,et al.  Head injury and the risk of AD in the MIRAGE study , 2000, Neurology.

[21]  M. Breteler,et al.  Vascular risk factors for Alzheimer’s disease: An epidemiologic perspective , 2000, Neurobiology of Aging.

[22]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[23]  B L Miller,et al.  Estrogen for Alzheimer’s disease in women , 2000, Neurology.

[24]  C. Cotman,et al.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. , 2000, JAMA.

[25]  W. Jagust,et al.  The Role of APOE ∊4 in Modulating Effects of Other Risk Factors for Cognitive Decline in Elderly Persons , 1999 .

[26]  J. Witte,et al.  Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. , 1999, American journal of epidemiology.

[27]  R. Mayeux,et al.  The influence of smoking on the risk of Alzheimer’s disease , 1999, Neurology.

[28]  E G Tangalos,et al.  Postmenopausal estrogen replacement therapy and risk of AD , 1999, Neurology.

[29]  W. Jagust,et al.  The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. , 1999, JAMA.

[30]  E. Corder,et al.  The role of APOE polymorphisms in late-onset dementias , 1998, Cellular and Molecular Life Sciences CMLS.

[31]  A. Hofman,et al.  Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. , 1998, Archives of neurology.

[32]  A. Hofman,et al.  Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study , 1998, The Lancet.

[33]  L. Amaducci,et al.  Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging , 1998, Neurology.

[34]  K. Blennow,et al.  A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality , 1998, Journal of neurology, neurosurgery, and psychiatry.

[35]  K. Marder,et al.  Validity of family history for the diagnosis of dementia among siblings of patients with late‐onset Alzheimer's disease , 1998, Genetic epidemiology.

[36]  G. Schellenberg,et al.  Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. , 1997, American journal of epidemiology.

[37]  R. Brookmeyer,et al.  A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease , 1997, Neurology.

[38]  A. Hofman,et al.  Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. , 1997, JAMA.

[39]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[40]  V. Henderson,et al.  Estrogen replacement therapy and risk of Alzheimer disease. , 1996, Archives of internal medicine.

[41]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[42]  R. Katzman.,et al.  Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks? , 1996, Neurology.

[43]  A D Roses,et al.  Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.

[44]  B. Tycko,et al.  Synergistic Effects of Traumatic Head Injury and Apolipoprotein-epsilon4 in Patients With Alzheimer's Disease , 1995, Neurology.

[45]  B. Tycko,et al.  Apolipoprotein E and alzheimer's disease: Ethnic variation in genotypic risks , 1995, Annals of neurology.

[46]  J. Buckwalter,et al.  Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. , 1994, Archives of neurology.

[47]  Yaakov Stern,et al.  Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community‐dwelling elderly persons and their first‐degree relatives , 1993, Annals of neurology.

[48]  R. Mayeux,et al.  Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. , 1992, Archives of neurology.

[49]  Bruce G. Link,et al.  Diagnosis of dementia in a heterogeneous population. A comparison of paradigm-based diagnosis and physician's diagnosis. , 1992, Archives of neurology.

[50]  M. Napoli,et al.  Postmenopausal Estrogen and Prevention Bias , 1992, Annals of Internal Medicine.

[51]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[52]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.